+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

IPX203 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

IPX203 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
Cervical Dystonia - Epidemiology Forecast - 2034 - Product Thumbnail Image

Cervical Dystonia - Epidemiology Forecast - 2034

  • Report
  • February 2024
  • 75 Pages
  • Global
From
Tuberous Sclerosis - Pipeline Insight, 2024 - Product Thumbnail Image

Tuberous Sclerosis - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 60 Pages
  • Global
From
From
LRRK2 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

LRRK2 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
GABA A receptor agonist - Pipeline Insight, 2024 - Product Thumbnail Image

GABA A receptor agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Dopamine D2 receptor antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine D2 receptor antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Dopamine D1 receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine D1 receptor antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Dopamine receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
Alpha4beta7 integrin antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha4beta7 integrin antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Trk (TrkB) receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Trk (TrkB) receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Nerve growth factor inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Nerve growth factor inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Epilepsy - Epidemiology Forecast - 2032 - Product Thumbnail Image

Epilepsy - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 197 Pages
  • Global
From
D Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

D Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more